Obinutuzumab versus rituximab for newly diagnosed ALL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study compares two antibody treatments—obinutuzumab and rituximab—for newly diagnosed acute lymphoblastic leukemia (ALL) that has the CD20 marker. It aims to see which treatment works better and is safe for people whose leukemia cells have CD20.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have newly diagnosed ALL, and CD20 is found on at least 20% of your leukemia cells
- You can sign a consent form to join the study
- If you can get pregnant, you can use effective birth control during the study
- You do not have lymphoblastic lymphoma with less than 20% blasts in the bone marrow
- You don’t have major heart problems or serious uncontrolled infections or organ problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well obinutuzumab (an antibody medicine) combined with chemotherapy works for people whose CD20-positive B-cell lymphoma has come back or didn’t respond to initial treatment. It may help by attacking lymphoma cells that carry the CD20 marker.
This study compares two antibody medicines, obinutuzumab and rituximab, to prevent relapses of steroid-dependent or frequently relapsing nephrotic syndrome in children. It looks at whether one option works better and is safer, including infection risk.
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
This study tests a new drug called obinutuzumab to see if it can keep nephrotic syndrome from coming back in adults who need repeated rituximab treatments. The goal is to see if obinutuzumab works better at controlling the disease compared to current care.
This trial tests a combination of two medications (obinutuzumab and CC-99282) for people with a type of lymphoma called follicular lymphoma that has not been treated before and is considered high-burden (meaning it is widespread or growing quickly). The goal is to see if this combination helps control the cancer.
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
Hear when a new CD20-positive Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.